“Biobanking market set to grow to $4.2bn by 2024” says new Visiongain report

23 May 2019
Pharma

Visiongain has launched a new pharma report Biobanking Market Forecasts 2019-2029: Research, Therapeutic, Human Tissue, Stem Cells, Commercial Sector, Public Sector, Umbilical Cord Banking, Adult Stem Cell Banking, Consumables, Equipment, Services, Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems.

The demand for resources stored in biobanks is growing worldwide. The value of human biologic specimens for research is increasing. Biologic specimens housed in biobanks are being increasingly used in epidemiological investigations into various diseases. The overall biobanking market is estimated to grow at a CAGR of 6.6% in the first half of the forecast period. The use of biobanks for therapeutic applications is also increasing, such as in the stem cell banking sector. Efforts are being made to establish biobanking networks, harmonising biobanking practices and condensing that industry.

The lead analyst of the report commented "Biobanking infrastructure is improving at a global level with the establishment of large-scale national biobanks, population biobank projects, virtual biobanks and networking at national and international level. The result of this improving infrastructure is the condensing of the biobanking industry and expanding access to samples. This will drive growth during the forecast period.

For innovative research to drive the biobanking industry, the biobanking industry must recognise the importance of standardisation and harmonisation. Biobanks must also shift towards integrated systems for higher efficiency. Integrating hardware, software, consumables and automation can allow a biobank to function more smoothly and quickly."

Leading companies featured in the report include Asterand Bioscience (Stemgent), Biogenea Pharmaceuticals, Biopta (ReproCELL), BioServe, Caladrius Biosciences, China Cord Blood Corp, Cord Blood America, Danaher, LifebankUSA, Qiagen, StemLife, Thermo Fisher Scientific, Inc., Tissue Solutions, ViaCord and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever